Neovacs is developing new treatments for autoimmune diseases: Kinoid ®
Kinoid ® therapeutic vaccines allow the immune system to generate "natural" polyclonal antibodies, which can act against the overproduction of cytokines that cause the disease. Kinoids® are obtained by combining the targeted cytokine with a carrier protein, which makes it immunogenic.
In lupus, the Kinoids produce antibodies directed against the cytokine interferon alpha (IFNα). In asthma, Kinoids® produce antibodies directed against the cytokines interleukin-4 (IL-4) and interleukin-13 (IL-13).
Kinoid injection to the patient induces natural polyclonal antibodies directed against different parts of the cytokine, neutralizing it more efficiently.
New programs are currently testing other autoantigens such as IgE.